Literature DB >> 28606969

Faecal microbiota study reveals specific dysbiosis in spondyloarthritis.

Maxime Breban1,2,3, Julien Tap4,5, Ariane Leboime3, Roula Said-Nahal3, Philippe Langella4, Gilles Chiocchia1,2,6, Jean-Pierre Furet4, Harry Sokol4,7,8.   

Abstract

OBJECTIVE: Altered microbiota composition or dysbiosis is suspected to be implicated in the pathogenesis of chronic inflammatory diseases, such as spondyloarthritis (SpA) and rheumatoid arthritis (RA).
METHODS: 16S ribosomal RNA gene sequencing was performed on faecal DNA isolated from stool samples in two consecutive cross-sectional cohorts, each comprising three groups of adult volunteers: SpA, RA and healthy controls (HCs). In the second study, HCs comprised a majority of aged-matched siblings of patients with known HLA-B27 status. Alpha and beta diversities were assessed using QIIME, and comparisons were performed using linear discriminant analysis effect size to examine differences between groups.
RESULTS: In both cohorts, dysbiosis was evidenced in SpA and RA, as compared with HCs, and was disease specific. A restriction of microbiota biodiversity was detected in both disease groups. The most striking change was a twofold to threefold increased abundance of Ruminococcus gnavus in SpA, as compared with both RA and HCs that was significant in both studies and positively correlated with disease activity in patients having a history of inflammatory bowel disease (IBD). Among HCs, significant difference in microbiota composition were also detected between HLA-B27+ and HLA-B27 negative siblings, suggesting that genetic background may influence gut microbiota composition.
CONCLUSION: Our results suggest that distinctive dysbiosis characterise both SpA and RA and evidence a reproducible increase in R. gnavus that appears specific for SpA and a marker of disease activity. This observation is consistent with the known proinflammatory role of this bacteria and its association with IBD. It may provide an explanation for the link that exists between SpA and IBD. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  ankylosing spondylitis; infection; inflammation; rheumatoid arthritis; spondyloarthritis

Mesh:

Substances:

Year:  2017        PMID: 28606969     DOI: 10.1136/annrheumdis-2016-211064

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  97 in total

Review 1.  Dendritic cells in the pathogenesis of ankylosing spondylitis and axial spondyloarthritis.

Authors:  Gleb Slobodin; Itzhak Rosner; Aharon Kessel
Journal:  Clin Rheumatol       Date:  2018-12-05       Impact factor: 2.980

Review 2.  Biomarker development for axial spondyloarthritis.

Authors:  Matthew A Brown; Zhixiu Li; Kim-Anh Lê Cao
Journal:  Nat Rev Rheumatol       Date:  2020-06-30       Impact factor: 20.543

3.  The gut microbiota modulator berberine ameliorates collagen-induced arthritis in rats by facilitating the generation of butyrate and adjusting the intestinal hypoxia and nitrate supply.

Authors:  Mengfan Yue; Yu Tao; Yulai Fang; Xingpan Lian; Qin Zhang; Yufeng Xia; Zhifeng Wei; Yue Dai
Journal:  FASEB J       Date:  2019-08-19       Impact factor: 5.191

4.  [Advances in research on axial spondyloarthritis].

Authors:  J Rademacher; D Poddubnyy
Journal:  Z Rheumatol       Date:  2018-09       Impact factor: 1.372

5.  B cell superantigens in the human intestinal microbiota.

Authors:  Jeffrey J Bunker; Christoph Drees; Andrea R Watson; Catherine H Plunkett; Cathryn R Nagler; Olaf Schneewind; A Murat Eren; Albert Bendelac
Journal:  Sci Transl Med       Date:  2019-08-28       Impact factor: 17.956

Review 6.  Revisiting the gut-joint axis: links between gut inflammation and spondyloarthritis.

Authors:  Eric Gracey; Lars Vereecke; Dermot McGovern; Mareike Fröhling; Georg Schett; Silvio Danese; Martine De Vos; Filip Van den Bosch; Dirk Elewaut
Journal:  Nat Rev Rheumatol       Date:  2020-07-13       Impact factor: 20.543

Review 7.  New advances in the understanding and treatment of axial spondyloarthritis: from chance to choice.

Authors:  Sayam Dubash; Dennis McGonagle; Helena Marzo-Ortega
Journal:  Ther Adv Chronic Dis       Date:  2017-12-14       Impact factor: 5.091

8.  Spondyloarthropathies: Ruminococcus on the horizon in arthritic disease.

Authors:  Lars Vereecke; Dirk Elewaut
Journal:  Nat Rev Rheumatol       Date:  2017-08-17       Impact factor: 20.543

Review 9.  Methods in microbiome research: Past, present, and future.

Authors:  Emily C Gotschlich; Robert A Colbert; Tejpal Gill
Journal:  Best Pract Res Clin Rheumatol       Date:  2020-04-24       Impact factor: 4.098

10.  [Update: enterogenic spondylarthritis].

Authors:  Elisabeth Märker-Hermann
Journal:  Z Rheumatol       Date:  2021-05-27       Impact factor: 1.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.